Allergan plc (NYSE:AGN) Shares Sold by Parametric Portfolio Associates LLC
Parametric Portfolio Associates LLC reduced its position in shares of Allergan plc (NYSE:AGN) by 20.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 582,676 shares of the company’s stock after selling 148,973 shares during the period. Parametric Portfolio Associates LLC owned about 0.18% of Allergan worth $97,557,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Motco acquired a new stake in Allergan in the second quarter valued at $29,000. Evolution Wealth Advisors LLC acquired a new stake in Allergan in the second quarter valued at $30,000. Berman Capital Advisors LLC raised its holdings in Allergan by 48.8% in the first quarter. Berman Capital Advisors LLC now owns 238 shares of the company’s stock valued at $34,000 after acquiring an additional 78 shares in the last quarter. Truewealth LLC raised its holdings in Allergan by 96.8% in the second quarter. Truewealth LLC now owns 248 shares of the company’s stock valued at $42,000 after acquiring an additional 122 shares in the last quarter. Finally, Liberty Wealth Management LLC raised its holdings in Allergan by 35.3% in the second quarter. Liberty Wealth Management LLC now owns 257 shares of the company’s stock valued at $43,000 after acquiring an additional 67 shares in the last quarter. 80.86% of the stock is currently owned by institutional investors and hedge funds.
AGN has been the topic of several recent analyst reports. Royal Bank of Canada reaffirmed a “hold” rating and issued a $178.00 price target on shares of Allergan in a report on Thursday, August 8th. SunTrust Banks upped their price target on shares of Allergan to $185.00 and gave the company a “buy” rating in a report on Wednesday, July 3rd. UBS Group upped their price target on shares of Allergan from $172.00 to $189.00 and gave the company a “buy” rating in a report on Thursday. JPMorgan Chase & Co. set a $200.00 price target on shares of Allergan and gave the company a “buy” rating in a report on Wednesday, June 19th. Finally, Barclays upped their price target on shares of Allergan from $176.00 to $188.00 and gave the company an “equal weight” rating in a report on Wednesday, August 7th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and six have given a buy rating to the stock. Allergan presently has an average rating of “Hold” and a consensus target price of $178.75.
Allergan (NYSE:AGN) last issued its earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.34 by $0.04. The company had revenue of $4.09 billion for the quarter, compared to analysts’ expectations of $3.93 billion. Allergan had a negative net margin of 54.25% and a positive return on equity of 8.73%. The firm’s revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the company earned $4.42 earnings per share. Analysts predict that Allergan plc will post 16.69 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 13th. Shareholders of record on Tuesday, August 13th will be issued a dividend of $0.74 per share. The ex-dividend date is Monday, August 12th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.78%. Allergan’s dividend payout ratio (DPR) is 17.74%.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Article: How prevalent are 12b-1 fees?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.